What are the diagnostic criteria and treatment options for dialysis disequilibrium syndrome?

Dialysis Disequilibrium Syndrome: Diagnosis and Treatment

Diagnosis

Dialysis disequilibrium syndrome (DDS) is a clinical diagnosis of exclusion made when neurological symptoms develop during or within hours after hemodialysis initiation in patients with severe uremia, particularly when other causes have been ruled out. 1, 2

Clinical Presentation

The syndrome manifests with a spectrum of neurological symptoms that typically appear during or shortly after dialysis:

Mild symptoms:

• Headache (24.8% of cases)
• Nausea (25.2%)
• Vomiting (23.9%)
• Muscle cramps (18.1%)

Severe symptoms:

• Altered level of consciousness (8.8%)
• Confusion (4.4%)
• Seizures (4.9%)
• Disorientation and stupor 3, 4

Atypical presentations may include hypoxia and subtle neurological signs without overt seizures, particularly in patients unable to communicate symptoms 5.

High-Risk Patient Identification

DDS occurs most commonly in:

• First-time dialysis patients with markedly elevated urea (typically BUN >150-200 mg/dL)
• Patients with severe metabolic acidosis (bicarbonate <10 mEq/L)
• Those who have missed regular dialysis treatments
• Patients with acute kidney injury requiring rapid correction 1, 3, 4

Diagnostic Workup

Since DDS is a diagnosis of exclusion, rule out:

• Structural brain lesions (CT/MRI)
• Seizure disorders (EEG if available)
• Electrolyte disturbances (hyponatremia, hypoglycemia)
• Hypertensive encephalopathy
• Stroke or intracranial hemorrhage 2

Key diagnostic clue: Temporal relationship between symptom onset and dialysis, with rapid improvement (typically within 12-48 hours) after supportive treatment 4, 2.

---

Treatment

Acute Management

When DDS develops during dialysis, immediately stop or slow the treatment and administer hyperosmolar therapy to reduce cerebral edema. 4

Immediate interventions:

1. Stop or significantly reduce dialysis parameters:

   • Decrease blood flow rate
   • Reduce dialysate flow rate
   • Consider terminating the session 2, 5

2. Hyperosmolar therapy (choose one or both):

   • Mannitol 20%: 0.5 g/kg IV bolus (typically 40 g)
   • Hypertonic saline 3%: 30 mL bolus, then 50 mL/h infusion
   • Target: Maintain serum sodium 145-155 mEq/L 4, 6

3. Supportive care:

   • Oxygen supplementation for hypoxia
   • Anticonvulsants if seizures occur
   • ICU monitoring for severe cases 4, 5

Prevention Strategies (Primary Approach)

Prevention is the cornerstone of DDS management and is achieved through gradual, gentle dialysis initiation in high-risk patients. 1, 3

Structured protocol for first dialysis session in patients with severe uremia (BUN >150-200 mg/dL):

1. Target low urea reduction ratio (URR):

   • First session: URR 20-30% (not >40%)
   • Second session: URR 30-35%
   • Third session: URR 30-35%
   • Gradually increase to standard targets thereafter 3, 4, 6

2. Reduce dialysis intensity:

   • Shorten treatment time: 2-2.5 hours (not the standard 3-4 hours)
   • Lower blood flow rate: 150-200 mL/min initially
   • Lower dialysate flow rate: 300-500 mL/min
   • Use smaller dialyzer surface area if available 3, 6

3. Dialysate modifications:

   • Linear dialysate sodium profiling (gradually increasing sodium concentration during treatment)
   • Consider higher dialysate sodium (145-150 mEq/L) 6

4. Prophylactic osmotic agents:

   • Mannitol 20%: 0.25-0.5 g/kg during or at end of dialysis
   • 25% dextrose: Can be administered prophylactically 6

5. Control metabolic acidosis correction:

   • Avoid rapid bicarbonate correction
   • Target bicarbonate rise <10 mEq/L per session
   • Severe acidosis (bicarbonate <5 mEq/L) is a major risk factor 4

Alternative Dialysis Modalities

For patients at very high risk or those who develop DDS despite preventive measures, switch to continuous renal replacement therapy (CRRT) or peritoneal dialysis. 7, 3

• CRRT (CVVH/CVVHDF): Associated with only 38% ICP elevation vs. 73% with intermittent hemodialysis in high-risk patients 7
• Peritoneal dialysis: DDS has not been reported with PD 1
• Twelve studies switching from HD to CVVH/CVVHDF or PD reported zero DDS symptoms 3

Subsequent Dialysis Sessions

After DDS occurrence:

• Resume dialysis with reduced blood flow (150-200 mL/min) and dialysate flow (300-500 mL/min)
• Continue prophylactic mannitol
• Gradually increase intensity over 1-2 weeks as tolerated 2, 5

---

Critical Pitfalls to Avoid

1. Do not aim for standard URR (>65%) or Kt/V (>1.2) in the first dialysis session when BUN >150 mg/dL—this dramatically increases DDS risk 4, 6

2. Do not rapidly correct severe metabolic acidosis—bicarbonate jumps >10 mEq/L correlate with DDS severity 4

3. Do not dismiss subtle neurological signs (staring, decreased responsiveness) as "just uremia"—these may be early DDS 5

4. Do not delay hyperosmolar therapy once DDS is suspected—cerebral edema can progress rapidly 4

5. Do not use standard dialysis parameters in patients who missed multiple treatments—treat them as first-time dialysis patients 1

---

Outcome Expectations

With appropriate prevention and management:

• Mortality from DDS is preventable 1, 6
• Neurological recovery is typically complete within 12-48 hours 4, 2
• Structured protocols reduce DDS incidence to 2-4% in high-risk populations 6
• Long-term neurological outcomes are excellent when promptly treated 4, 6